Patient and immunological factors associated with delayed clearance of mucosal SARS-CoV-2 RNA and symptom persistence
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
Serial blood and mucosal samples were characterized for 102 participants enrolled a median of 7.0 days post-COVID-19 diagnosis. Mucosal RNA was detectable a median 31.5 (95% CI 20.5 - 63.5) days, with persistence ≥1 month associated with obesity (BMI ≥30, OR 3.9, 95% CI 1.2 - 13.8) but not age, sex, or chronic conditions. Fifteen participants had likely reinfection; lower serum anti-S IgG levels were associated with reinfection risk. Nearly half of participants (47%) reported symptoms lasting ≥2-3 months; persistence ≥3 months was associated with BMI ≥30 (OR = 4.2 95% CI 1.1 - 12.8) and peak anti-S and anti-NC antibody levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - (2024) vom: 12. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stone, Mars [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Revised 12.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/infdis/jiae132 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36960590X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36960590X | ||
| 003 | DE-627 | ||
| 005 | 20240313235038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiae132 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM36960590X | ||
| 035 | |a (NLM)38470857 | ||
| 035 | |a (PII)jiae132 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stone, Mars |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient and immunological factors associated with delayed clearance of mucosal SARS-CoV-2 RNA and symptom persistence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a Serial blood and mucosal samples were characterized for 102 participants enrolled a median of 7.0 days post-COVID-19 diagnosis. Mucosal RNA was detectable a median 31.5 (95% CI 20.5 - 63.5) days, with persistence ≥1 month associated with obesity (BMI ≥30, OR 3.9, 95% CI 1.2 - 13.8) but not age, sex, or chronic conditions. Fifteen participants had likely reinfection; lower serum anti-S IgG levels were associated with reinfection risk. Nearly half of participants (47%) reported symptoms lasting ≥2-3 months; persistence ≥3 months was associated with BMI ≥30 (OR = 4.2 95% CI 1.1 - 12.8) and peak anti-S and anti-NC antibody levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a long-COVID | |
| 650 | 4 | |a obesity | |
| 700 | 1 | |a Spencer, Bryan R |e verfasserin |4 aut | |
| 700 | 1 | |a Warden, Donald E |e verfasserin |4 aut | |
| 700 | 1 | |a Fink, Rebecca V |e verfasserin |4 aut | |
| 700 | 1 | |a Saa, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Leddy, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Mulach-Vannoy, Jackie |e verfasserin |4 aut | |
| 700 | 1 | |a Townsend, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Krysztof, David |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Alexandria N |e verfasserin |4 aut | |
| 700 | 1 | |a Di Germanio, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Kessler, Debra A |e verfasserin |4 aut | |
| 700 | 1 | |a Kleinman, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Busch, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Norris, Philip J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g (2024) vom: 12. März |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiae132 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 03 | ||